OPEN SESSION

FOR INFORMATION ONLY  
(No formal action is requested at this time)

1. HIV/AIDS Cure Partnership between GlaxoSmithKline & UNC-CH  
   David Routh, Vice Chancellor for University Development  
   Mark Meares, Associate Vice Chancellor for Corporate &  
   Foundation Relations and Talent Management

2. Update from the Office of the Vice Chancellor for Commercialization  
   & Economic Development  
   Judith Cone, Interim Vice Chancellor for Commercialization &  
   Economic Development

3. Strategic Partnerships  
   Bryant Moore, Director of Strategic Partnerships  
   (Attachment A)

4. Summary of the Innovation & Impact Committee’s Work  
   Phil Clay, UNC Board of Trustees

*Some of the business to be conducted is authorized by the N.C. Open Meetings Law to be  
conducted in closed session.
Industry Relations Update

May 2015
Meeting of the UNC-CH Board of Trustees
Innovation and Impact Committee

David S. Routh
Vice Chancellor for Development

Mark Meares
Associate Vice Chancellor for Corporate and Foundation Relations
Industry Research Support

In 2013:

• UNC ranked 9th in all research expenditures in the country
• UNC ranked 35th in business and industry support for research ($28.5M)
• Duke ranked 2nd ($177M)
• NC State ranked 16th ($46M)
UNC Industry Relations

• Proactive approach
• 2.5 FTE industry relations officers
• Create virtual and actual portal
• Individual grants to complex partnerships
• Cross-campus collaboration with vice chancellors for commercialization/economic development and research
• Goal: Triple industry research support in five years
Finding a cure for HIV/AIDS will require a new model of industry, academy, and government collaboration.

- **QURA THERAPEUTICS**
  - 50/50 Ownership
  - Holds partners cash and intellectual property

- **HIV Cure Center**
  - Collaborative research in an academic setting

- **Other partners**

- **gsk**
  - Funding

- **World-class researchers and know-how**

- **Facilities and infrastructure**

- **Access to federal and other sources of funding**

- **World-class researchers and know-how**

- **Funding**

- **IP**

- **Other $$**
IMPACT
Putting Important Ideas to Use

UNC Board of Trustees
Innovation & Impact Committee, Chair Phil Clay

Judith Cone, Interim Vice Chancellor for Commercialization & Economic Development
Special Assistant to the Chancellor for Innovation & Entrepreneurship
May 27, 2015
Phase 2 Timeline

1/10 Chancellor Holden Thorp Kicks off the Innovation Roadmap Process

2010
- 1/10 Strategy Group of Faculty, Students, Innovation Circle

2011
- 1/11 BOT Members involved with Roadmap ONGOING
- 10/10 Roadmap Released
- 11/11 Innovation Circle Mtg

2012
- 10/12 Two-Year Progress Report & Innovation Circle Mtg
- 11/11 Innovation Circle Mtg

2013
- 5/13 BOG Releases 2013-18 Strategic Directions Plan
- 7/13 BOT Carol Folt Hired; Innovation & Impact Committee Holds 1st mtg
- 10/13 Carol Folt Installed as 11th Chancellor
- 11/13 Innovation Circle Mtg

2014
- 2/14 BOG Holds Mtg on Commercialization
- 5/14 BOT I&I Committee Memo to Leadership
- 2/14 Chancellor Folt presents on Commercialization to BOG
- 9/13 UNC I&E Network 1st Mtg
- 11/14 MOU: Kickstart, Kenan Institute, CES, OTD, I&E

2015
- 1/15 CRVF Carolina Research Venture Fund $5M+
- 2/15 Chancellor Folt Creates VC of Comm.
- 3/15 Governor seeks funding for I2J from Legislature

BUILDING BLOCKS OF INNOVATION

- 3/12 Space
  CUBE at Campus Y Opens; CS E'rs Lounge

- 5/13 Space
  Launch Chapel Hill Opens

- 6/13 Space
  CreatorSpace Faculty Working Group

- 7/13 Space
  1789 Venture Lab Opens

- 7/14 Space
  Faculty Working Group Presents to Provost

- 2/14*** Space
  Lost Space for Faculty Entrepreneurs

- 4/15 Space
  Start planning Innovation Hubs

- 2015
  Space
  Opening of CreatorSpace in Murray Hall
BIOGRAPHY

Bryant M. Moore, PhD

Director of Strategic Partnerships, Office of Commercialization & Economic Development at the University of North Carolina at Chapel Hill

Bryant is an executive with over 30 years of broad leadership experience developing medical products. He has an extensive background in product development, technology evaluation and business development which spans the areas of clinical diagnostics, endoscopy and sports medicine, cardiology and ophthalmology. Most recently, he was Global Head, Refractive R&D for Abbott Medical Optics, a division of Abbott Laboratories. Prior to Abbott he held several key leadership roles in Medtronic’s Cardiac Rhythm Disease Management business. He was Vice President, External Partnerships and Technology Assessment having accountability for developing strategic partnerships with early-stage start-ups, universities and other external research organizations to help the business grow the product pipeline. Prior to this role he held the positions of Vice President Biotechnology and Technology Scouting, Vice President Product Development and Technology and Vice President Applied Technology and Central Engineering.

Prior to Medtronic, he was Worldwide Vice President Research and Development for Smith & Nephew’s endoscopy business. He was accountable for development of minimally invasive surgery products for the Arthroscopy/Sports Medicine marketplace.

Prior to Smith & Nephew, he worked for Johnson & Johnson where he held several leadership positions within their clinical diagnostics business. These positions were Vice President Assay R&D, Vice President Research & Development and Director of Technology and Hemostasis.

Prior to Johnson & Johnson, he worked as Manager of Hemostasis for Organan Teknika, a division of Dutch Multinational Akzo.

He began his career as a scientist working in clinical chemistry R&D for the DuPont Company in Wilmington, DE.

Bryant holds a BS degree in Chemistry from North Carolina A&T State University, Greensboro, NC and a PhD degree in Biochemistry from the University of North Carolina at Chapel Hill, Chapel Hill, NC.